FilingReader Intelligence

Mankind Pharma reports 19% revenue growth, acquires BSV

July 15, 2025 at 07:10 PM UTCBy FilingReader AI

Mankind Pharma reported revenue of ₹12,207.44 crores for financial year 2024-25, marking 19% year-on-year growth, with net profit of ₹2,006.59 crores.

The company acquired a 100% stake in Bharat Serums and Vaccines Limited for ₹13,768 crore, expanding its presence in complex super-specialty segments.

Mankind Pharma also entered licensing agreements with AstraZeneca, Novartis, and Innovent Biologics to strengthen its product portfolio. The company increased R&D allocation to 2.5%-3.0% of revenue for FY2026.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

BSE:MANKINDBombay Stock Exchange

News Alerts

Get instant email alerts when Mankind Pharma publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →